Annual Report 2003–04

Technology Transfer Licensee of CUHK's Non-invasive Prenatal Diagnosis Technologies Listed in GEM Plasmagene Biosciences Ltd., established in January 2001, is engaged in business relating to the medical diagnosis of cancerous, prenatal, and other major diseases. Its core businesses are based on a number of patented/patent- pending diagnosis technologies for cancerous and prenatal diseases developed by Prof. Dennis Lo of the Chemical Pathology Department. The company obtained exclusive licence from the University to commercialize these technologies. On 18th June 2004, Plasmagene Biosciences was listed on the Growth Enterprise Market (GEM) with market capitalization of HK$163.9 million. Novel Input and Sensing Device - Micro Input Devices System (MIDS) MIDS, a novel virtual input device, is developed by Mr. Alan Hiu-Fung Lam, a Ph.D. candidate of the Department of Automation and Computer- Aided Engineering, and Prof. Wen J. Li, Mr. Lam's Ph.D. supervisor. Mr. Lam, who studied virtual reality for his master degree, set out to develop a virtual input device to replace traditional computer mouse and keyboard in his Ph.D. thesis. After two years of hard work, Mr. Lam and his team finally developed a driver interface program that can turn even very small hand 科技轉移 中大醫學發明協助開發商在創業板 上市 普施基因生物科技過去數年，與 中大簽訂數項專利授權協議，把 化學病理學系盧煜明敎授發明的 數項專利診斷技術商品化，其中 包括非入侵性產前檢查技術及從 人體血漿內的核糖核酸濃度檢測 癌症的技術。普施基因生物科技 有限公司於二零零一年成立，專 門從事與癌症、先天性及其他主 要疾病有關的醫療診斷服務。該 公司於二零零四年六月十八日在 香港創業板上市，總資本額為一 億六千三百九十萬港元。 感應手指動作的微型輸入系統 自動化與計算機輔助工程學系博士生林曉鋒在導 師李文榮敎授的指導下，成功硏製出一套利用指 環控制的微型輸入系統（ MIDS) 。林曉鋒在碩士課 學習了虛擬真實技術後，便萌生硏製虛擬滑鼠及 虛擬鍵盤的念頭，並以微型輸入系統作為博士論 文的題目。經過兩年的努力，終硏製出一套能感 應手指動作並將之轉化為電腦指令的微型輸入系 統。該系統或可取代傳統的電腦滑鼠及鍵盤。林 曉鋒已與其他硏究員合組公司，並與大學簽訂授 權協議，繼續開發是項技術，推廣虛擬鍵盤、滑 鼠及遊戲機控制器。 漢達古文獻資料庫中心 「漢達古文獻資料庫中心」於一九八八年成立，目 的是將中國古代全部傳世及出土文獻加以校訂、 林曉鋒發明的指環控制器 Demonstration f Mr. Alan Fung's invention 盧煜 明敎授（右）、研究及科技事務處主任 顏文慧女士（左）與普施基因生物科技主席 楊華顯醫生（右二）慶祝該公司上市 Prof. Dennis Lo (right), Ms. Alice Ngan (left), director of the Research and Technology Administration Office, and Dr. Alex Yeung, CEO of Plasmagen Biosciences Ltd. (right 2), celebrating their CU- industry collaboration 研 究 Research 45